Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

Exclusion Criteria

• •Any active or past AIDS-defining illness with the exception of minimal (less than 10 lesions) cutaneous Kaposi's sarcoma
• •History of a CD4+ T-cell count ≤200/μL
• •Grade 2 or higher CPK laboratory result
• •Use of any known immunomodulatory therapy within 4 weeks prior to study entry
• •Any malignancy requiring systemic or local toxic chemotherapy. Local radiation will be allowed
• •Pregnancy or breast-feeding
• •Uncontrolled diabetes mellitus
• •Major organ transplantation
• •Active alcohol or substance abuse or psychiatric illness, which in the opinion of the investigator will interfere with adherence to study requirements
• •Clinically significant neurological disorder occurring within 1 year prior to study entry
• •Use of systemic corticosteroids for 4 weeks within 3 months prior to study entry
• •Presence of any chronic disease that in the opinion of the investigator might affect subject safety
• •History of previous vaccination with an HIV-1 vaccine except where documentation of placebo is available
• •History of cardiac arrhythmia
• •History or evidence of autoimmune disease
• •Allergies to bupivacaine or similar anesthetic
• •Metal implants at the site of injection
• •Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infections disease) illness
• •Any other conditions judged by the investigator that would limit the evaluation of a subject